TLC is creating a pipeline of new therapies to
treat blood cancers using less traditional forms of drug discovery and development.
Studies conducted in China and the United States demonstrated that arsenic — long considered a carcinogen —
helps treat a blood cancer called acute promyelocytic leukemia.
Keith Brown, an epigenetics researcher at the University of Bristol, UK, says that de-methylating agents
already treat some blood cancers successfully, but it is not clear how they work.
«One of the major limitations we see
in treating blood cancers is the failure to clear cancer cells from the bone marrow,» said Flavia Pernasetti, PhD, of Pfizer Oncology Research and Development.
«New antibody uses 1 - 2 punch to
potentially treat blood cancers: Preclinical studies show new antibody simultaneously targets cancer cells while making them more vulnerable to chemotherapy.»
«Arthritis drug could
treat blood cancer patients, breakthrough finds: Blood cancer sufferers could be treated with a simple arthritis drug, scientists have discovered.»
At the Maharaj Institute, our team has been
treating blood cancers with evidence - based chemotherapy regimens on a totally outpatient basis; a shift in the care of these aggressive malignancies, which normally is done at the hospital.
Adoptive cell therapy for hard - to -
treat blood cancers, after all, are widely expected to be the standard of care within a decade, and it should therefore grow to become one of the most lucrative markets in all of biotech.
In the early 2000s, Johns Hopkins scientists Leo Luznik and Ephraim Fuchs found that giving patients high doses of cyclophosphamide — a drug derived from nitrogen mustard and used to
treat blood cancers — three days after bone marrow transplant successfully thwarts acute and chronic GVHD.
HSCT is effectively used today as a form of «replacement» therapy for patients with hard - to -
treat blood cancers, providing healthy cells from either the patient (autologous transplantation) or from a donor (allogeneic transplantation) to better equip patients to fight the disease on their own.